CooperCompanies Q3 2026: Tax Windfall, Modest Growth, and a Strategic Reset

Ticker: COO | Nasdaq: COO • Earnings press release for the quarter ended July 31, 2026

Key numbers at a glance

Revenue: $1.066 billion, up 1% year over year, including 1% organic growth.
GAAP diluted EPS: $2.24, versus $0.49 in the prior year's third quarter, largely aided by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination.
Non-GAAP diluted EPS: $1.15, up 4% from last year's third quarter.
Free cash flow: $273.0 million, up 66% from the prior year's third quarter; cash provided by operations of $341.7 million less capex of $68.7 million.
Share repurchases: $339.1 million of common stock completed.
Margins: Gross margin 67% (non-GAAP 67%), operating margin 21% (non-GAAP 26%).
Interest expense: $21.5 million, down from $25.4 million in the prior year’s third quarter.

Strategic review and shareholder value

The company notes it completed its strategic review process and announced actions to enhance shareholder value. Details are said to be provided in a separate press release issued today. In other words, the business is signaling a broader reshuffle of priorities beyond the quarterly numbers, with capital allocation and structural moves on deck.

From the top

“This quarter included a number of notable developments including earnings exceeding expectations, record free cash flow, solid fertility growth at CooperSurgical, and a favorable completion of a significant tax matter. At CooperVision, however, we proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4,” said Al White, President and CEO of CooperCompanies. “Following the completion of the strategic review, we are focused on profitable growth, strong cash flow generation, disciplined capital allocation, and maximizing long-term shareholder value.”

Segment highlights: CooperVision and CVI

CooperVision (CVI) revenue was $717.0 million, roughly flat versus the prior year’s third quarter on a reported, constant currency, and organic basis. The report also provides a note on “Revenue by category,” underscoring portfolio-level stability amid broader margin dynamics. The quarter reinforces how the company’s segments—spanning medical devices and fertility solutions—contribute to a consolidated narrative of restrained top-line growth coupled with improving profitability metrics.

What this could portend for the sector and peers

Finance writers will spot a few throughlines. first, the tax benefit that flattered GAAP EPS signals a one-off asymmetry that could obscure underlying operating performance. EPS consensus for a steady 2026 narrative may be clouded unless management couples these results with sustainable growth in organic sales or margin expansion. The 1% revenue uptick in a diversified medical devices portfolio suggests resilience, but the absence of explicit revenue forecasts means investors will seek color on Q4 expectations and long-run trajectory from management.

Second, the sizable share repurchase and the declared completion of a strategic review imply a willingness to reallocate capital toward shareholder value rather than pursue aggressive growth alone. For peers, this can set a tempo: buybacks paired with strategic clarity could become a common theme if tax and working-capital dynamics cooperate.

Finally, the commentary around CooperVision’s inventory adjustment hints at a familiar macro tension—managing channel inventory in a business that spans consumer/physician channels while trying to protect near-term earnings power. If other sector players face similar inventory normalization or mix shifts, the next few quarters could be a test of how well firms translate disciplined cost controls into durable margins, even as the top line remains modestly reined in.

Notes on earnings terms and what to watch

In this report, COO’s numbers appear with a clear explicit EPS figure (GAAP) and a reconciled Non-GAAP EPS. The piece references “earnings exceeding expectations” in the CEO’s quote, but readers should treat that as a company-side characterization rather than a guaranteed earnings surprise versus external EPS consensus. The lack of a stated revenue forecast means investors will be listening for any forward-looking guidance in future communications. Keep an eye on EPS trends (GAAP and non-GAAP), revenue trajectory, and how the company allocates capital—especially the balance between buybacks and strategic investments—as a key signal for how the stock might trade into the next earnings cycle.